Self-assembling peptides: Potential role in tumor targeting

Current Pharmaceutical Biotechnology

Volumn 12, Issue 8, 2011, Pages 1089-1100

  Sadatmousavi, Parisa ^a   Soltani, M ^a   Nazarian, Reyhaneh ^a   Jafari, Mousa ^a   Chen, P ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Cell targeting peptide; Combinatorial peptide library; Ionic complementary; Phage display; Self assembling peptide; Stimuli responsive; Tumor targeting; Vasculature

Indexed keywords

AMPHOPHILE; ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; BOLAAMPHIPHILE PEPTIDE; CARRIER PROTEIN; CELL TARGETING PEPTIDE; CYCLOPEPTIDE; DEXAMETHASONE; DOXORUBICIN; ELLIPTICINE; EPITOPE; FLUOROURACIL; IONIC COMPLEMENTARY PEPTIDE; IRON OXIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NANOCARRIER; PEPTIDE AMPHIPHILE; PEPTIDE LIBRARY; SELF ASSEMBLING PEPTIDE; SOBLIDOTIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BACTERIOPHAGE; BETA SHEET; BIOCOMPATIBILITY; BIODEGRADABILITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ELECTRICITY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOGENICITY; LUNG CANCER; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PH; PHAGE DISPLAY; PROTEIN ASSEMBLY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STATIC ELECTRICITY; SURFACE PROPERTY; TARGET CELL;

COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES; PEPTIDES, CYCLIC;

EID: 79959996154     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111796117409     Document Type: Review

References (122)

1. Peer, D.; Karp, J.; Hong, S.; Farokhzad, O.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2, 751-760.
2. Karp, G. Cell and Molecular Biology: Concepts and Experiments. John Wiley & Sons, Inc., New York, 2002.
3. Sapra, P.; Allen, T. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res., 2003, 42, 439-462.
4. Medina, O.; Zhu, Y.; Kairemo, K. Targeted liposomal drug delivery in cancer. Curr. Pharm. Des., 2004, 10, 2981-2989.
5. Couvreur, P.; Vauthier, C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res., 2006, 23, 1417-1450.
6. Danson, S.; Ferry, D.; Alakhov, V.; Margison, J.; Kerr, D.; Jowle, D.; Brampton, M.; Halbert, G.; Ranson, M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer. Br. J. Cancer, 2004, 90, 2085-2091.
7. Lee, K.S.; Chung, H.C.; Im, S.A.; Park, Y.H.; Kim, C.S.; Kim, S.; Rha, S.Y.; Lee, M.Y.; Ro, J. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat., 2008, 108, 2009-2014.
8. Wang, Y.; Caruso, F.; Zelikin, A.N.; Bansal, V. Templated synthesis of single-component polymer capsules and their application in drug delivery. Nano Lett., 2008, 8, 1741-1745.
9. Boas, U.; Heegaard, P.M.H. Dendrimers in drug research. Chem. Soc. Rev., 2004, 33, 43-63.
10. Liu, Z.; Sun, X.; Nakayama-Ratchford, N.; Hongjie D., Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano, 2007, 1, 50-56.
11. Fung, S.Y.; Yang, H.; Bhola, P.T.; Sadatmousavi, P.; Muzar, E.; Liu, M.; Chen, P. Self-Assembling Peptide as a Potential Carrier for Hydrophobic Anticancer Drug Ellipticine: Complexation, Release and in-vitro Delivery. Adv. Funct. Mater., 2009, 19, 74-83.
12. Gu, F.X.; Karnik, R.; Wang, A.Z.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R.S.; Farokhzad, O.C. Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2, 14-21.
13. Torchilin, V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm., 2009, 71, 431-444.
14. Torchilin, V.P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev., 2006, 58, 1532-1555.
15. Shukla, R.; Bansal, V.; Chaudhary, M.; Basu, A.; Bhonde, R.R.; Sastry, M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir: The ACS J. Sur. Colloids, 2005, 21, 10644-10654.
16. Sahoo, S.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today, 2003, 8, 1112-1120.
17. Moses, M.A.; Brem, H.; and Langer, R. Novel delivery systems in cancer chemotherapy. Sci. Med., 2003, 9, 264.
18. Fung, S.Y.; Keyes, C.; Duhamel, J.; Chen, P. Concentration effect on the aggregation of a self-assembling oligopeptide. Biophys. J., 2003, 85, 537-548.
19. Yang, H.; Fung, S.; Pritzker, M.; Chen, P. Modification of hydrophilic and hydrophobic surfaces using an Ionic-complementary peptide. PLoS One, 2007, 2, 1325.
20. Haldar, D.; Banerjee, A.; Drew, M.; Das, A.; Banerjee, A. First crystallographic signature of an acyclic peptide nanorod: molecular mechanism of nanorod formation by a self-assembled tetrapeptide. Chem. Commun., 2003, 1406-1407.
21. Matsui, H.; Gologan, B.; Pan, S.; Douberly, G.E.J. Controlled immobilization of peptide nanotube-templated metallic wires on Au surfaces. Eur. Phy. J., 2001, 16, 403-406.
22. Santoso, S.; Wonmuk Hwang, Hartman, H.; Shuguang Zhang, Self assembly of surfactant-like peptides with variable glycine tails to form nanotubes and nanovesicles. Nano Lett., 2002, 2, 687-691.
23. Hong, Y.; Legge, R.; Zhang, S.; Chen, P. Effect of amino acid sequence and pH on nanofiber formation of self-assembling peptides EAK16-II and EAK16-IV. Biomacromolecules, 2003, 4, 1433-1442.
24. Jun, S.; Hong, Y.; Imamura, H.; Ha, B.; Bechhoefer, J.; Chen, P. Self-assembly of the ionic peptide EAK16: The effect of charge distributions on self-assembly. Bio. J., 2004, 87,1249-1259
25. Mart, R.J.; Osborne, R.D.; Stevens, M.M.; Ulijn, R.V. Peptidebased stimuli-responsive biomaterials. Soft Matter, 2006, 2, 822-835.
26. Chen, P. Self-assembly of ionic-complementary peptides: a physicochemical viewpoint. Colloids Surf. A: Physiochem. Eng.Asp., 2005, 261, 3-24.
27. Niece, K.L.; Czeisler, C.; Sahni, V.; Tysseling-Mattiace, V.; Pashuck, E.T.; Kessler, J.A.; Stupp, S.I. Modification of gelation kinetics in bioactive peptide amphiphiles. Biomaterials, 2008, 29, 4501-4509.
28. Cui, H.; Webber, M.; Stupp, S. Self-Assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials. Pept. Sci., 2010, 94, 1-18.
29. Matsui, H.; Pan, S.; Gologan, B. Bolaamphiphile nanotubetemplated metallized wires. J. Phys. Chem. B., 2000, 104, 9576-9579.
30. Kogiso, M.; Ohnishi, S.; Yase, K.; Masuda, M.; Shimizu, T. Dicarboxylic oligopeptide bolaamphiphiles: Proton-triggered selfassembly of microtubes with loose solid surfaces. Langmuir, 1998, 14, 4978-4986.
31. Matsui, H.; Gologan, B. Crystalline glycylglycine bolaamphiphile tubules and their pH-sensitive structural transformation. J. Phys. Chem. B., 2000, 104, 3383-3386.
32. Ghadiri, M.R.; Granja, J.R.; Milligan, R.A.; McRee, D.E.; Khazanovich, N. Self-assembling organic nanotubes based on a cyclic peptide architecture. Nature, 1993, 366, 324-327.
33. Auria, G.; Vacatello, M.; Falcigno, L.; Paduano, L.; Mangiapia, G.; Calvanese, L.; Gambaretto, R.; Dettin, M.; Paolillo, L. Self assembling properties of ionic-complementary peptides. J. Pept. Sci., 2009, 15, 210-219.
34. Fung, S.; Yang, H.; Chen, P. Formation of colloidal suspension of hydrophobic compounds with an amphiphilic self-assembling peptide. Colloids Surf. B Biointerfaces, 2007, 55, 200-211.
35. Ulijn, R.V.; Smith, A.M. Designing peptide based nanomaterials. Chem. Soc. Rev., 2008, 37, 664-675.
36. Iyer, A.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today, 2006, 11, 812-818.
37. Aina, O.H.; Sroka, T.C.; Chen, M.; Lam, K.S. Therapeutic cancer targeting peptides. Biopolymers, 2002, 66, 184-199.
38. Juliano, R.L.; Alam, R.; Dixit, V.; Kang, H.M. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. Wiley Interdisciplinary Rev. Nanomed. Nanobiotechno., 2009, 1, 324-335.
39. Wu, X.L.; Kim, J.H.; Koo, H.; Bae, S.M.; Shin, H.; Kim, M.S.; Lee, B.; Park, R.; Kim, I.; Choi, K.; Kwon, I.C.; Kim, K.; Lee, D.S. Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy. Bioconjug Chem., 2010, 21, 208-213.
40. Ruoslahti, E. Targeting tumor vasculature with homing peptides from phage display. Semin. Cancer Biol., 2000,10, 435-442.
41. Burg, M.; Pasqualini, R.; Arap, W.; Ruoslahti, E.; Stallcup, W. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res., 1999, 59, 2869.
42. Arap, W.; Kolonin, M.; Trepel, M.; Lahdenranta, J.; Cardo-Vila, M.; Giordano, R.; Mintz, P.; Ardelt, P.; Yao, V.; Vidal, C.; Chen, L.; Flamm, A.; Valtanen, H.; Weavind, L.; Hicks, M.; Pollock, R.; Botz, G.; Bucana, C.; Koivunen, E.; Cahill, D.; Troncoso, P.; Baggerly, K.; Pentz, R.; Do, K.; Logothetis, C.; Pasqualini, R. Stepstoward mapping the human vasculature by phage display. Nat. Med., 2002, 8, 121-127.
43. Aina, O.; Liu, R.; Sutcliffe, J.; Marik, J.; Pan, C.; Lam, K. From combinatorial chemistry to cancer-targeting peptides. Mol. Pharm., 2007, 4, 631-651.
44. Poirson, F.; Kennedy, J.F. P. Chen, (Ed). Molecular interfacial phenomena of Polymers and Biopolymers, Woodhead Publishing Limited, Cambridge, 2005. Int. J. Biol. Macromol., 2007, 40, 167-168.
45. Paramonov, S.E.; Jun, H.; Hartgerink, J.D. Modulation of peptide-amphiphile nanofibers via phospholipid inclusions. Biomacro-molecules, 2006, 7, 24-26.
46. Hartgerink, J.D.; Beniash, E.; Stupp, S.I. Self-assembly and mineralization of peptide-amphiphile nanofibers. Science, 2001, 294, 1684-1688.
47. Silva, G.; Czeisler, C.; Niece, K.; Beniash, E.; Harrington, D.; Kessler, J.; Stupp, S. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science (Wash.), 2004, 303, 1352-1355.
48. Cui, H.; Stupp, S.I.; Muraoka, T.; Cheetham, A.G. Self-assembly of giant peptide nanobelts. Nano Lett., 2009, 9, 945-951.
49. Bar, R.; Cohen, M.; Addadi, L.; Geiger, B. Hierarchical assembly of cell-matrix adhesion complexes. Biochem. Soc. Trans., 2004, 32, 416-20.
50. Pierschbacher, M.D.; Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature, 1984, 309, 30-33.
51. Niece, K.L.; Hartgerink, J.D.; Donners, J.J.J.M.; Stupp, S.I. selfassembly combining two bioactive peptide-amphiphile molecules into nanofibers by electrostatic attraction. J. Am. Chem. Soc., 2003, 125, 7146-7147.
52. Stupp, S.I.; Beniash, E.; Hartgerink, J.D.; Storrie, H.; Stendahl, J.C. Self-assembling peptide amphiphile nanofiber matrices for cell entrapment. Acta Biomater., 2005, 1, 387-397.
53. Storrie, H.; Guler, M.O.; Abu-Amara, S.N.; Volberg, T.; Rao, M.; Geiger, B.; Stupp, S.I. Supramolecular crafting of cell adhesion. Biomaterials, 2007, 28, 4608-4618.
54. Zhang, S. Fabrication of novel biomaterials through molecular selfassembly. Nature Biotechnology, 2003, 21, 1171-1178.
55. Yang,; Khoe, U.; Xiumei Wang,; Horii, A.; Yokoi, H.; Shuguang Zhang, Designer self-assembling peptide nanomaterials. Nano Today, 2009, 4, 193-210.
56. Zhang, S.; Holmes, T.; Lockshin, C. Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc. Natl. Acad. Sci. USA, 1993, 90, 3334-3338
57. Pennisi, E. Material peptide. Sci. News, 1993, 143, 316-317.
58. Gelain, F.; Bottai, D.; Vescovi, A.; Zhang, S. Designer Self- Assembling Peptide Nanofiber Scaffolds for Adult Mouse Neural Stem Cell 3-Dimensional Cultures. PLoS One, 2006, 1, 119.
59. Yang, H.; Pritzker, M.; Fung, S.Y.; Sheng, Y.; Wang, W.; Chen, P. Anion effect on the nanostructure of a metal ion binding selfassembling peptide. Langmuir: The ACS J. Surf. Colloids, 2006, 22, 8553-8562.
60. Rudra, J.S.; Tian, Y.F.; Jung, J.P.; Collier, J.H. A self-assembling, peptide acting as an immune adjuvant. Proc. Nat. Acad. of Sci. USA, 2010, 107, 622(6)-628.
61. Barrow, C.J.; Zagorski, M.G. Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition. Science, 1991, 253, 179(4)-183.
62. Aggeli, A.; Bell, M.; Carrick, L.M.; Fishwick, C.W.G.; Harding, R.; Mawer, P.J.; Radford, S.E.; Strong, A.E.; Boden, N. pH as a Trigger of Peptide β-Sheet Self-Assembly and Reversible Switching between Nematic and Isotropic Phases. J. Am. Chem. Soc., 2003, 125, August.
63. Liu, R.; Enstrom, A.; Lam, K. Combinatorial peptide library methods for immunobiology research. Exp. Hematol., 2003, 31, 11-30.
64. Parmley, S.; Smith, G. Antibody-selectable filamentous fd phage vectors: Affinity purification of target genes. Gene, 1988, 73, 305-318.
65. Aina, O.H.; Marik, J.; Liu, R.; Lau, D.H.; Lam, K.S. Identification of novel targeting peptides for human ovarian cancer cells using " one-bead one-compound" combinatorial libraries. Mol. Cancer Ther., 2005, 806-813.
66. Winssinger, N.; Damoiseaux, R.; Tully, D.; Geierstanger, B.; Burdick, K.; Harris, J. PNA-encoded protease substrate microarrays.Chem. Biol., 2004, 11, 1328-1330.
67. Fukuda, M.; Ohyama, C.; Lowitz, K.; Matsuo, O.; Pasqualini, R.; Ruoslahti, E.; Fukuda, M. A peptide mimic of E-selectin ligand inhibitssialyl Lewis X-dependent lung colonization of tumor cells.Cancer Res., 2000, 60, 450-456.
68. Renschler, M.F.; Bhatt, R.R.; Dower, W.J. Synthetic peptideligands of the antigen binding receptor induce programmed celldeath in a human B-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A.,1994, 91, 3623-3627.
69. Buhl, L.; Szecsi, P.B.; Gisselø, G.G.; Schafer-Nielsen, C. Surface immunoglobulin on B lymphocytes as a potential target for specific peptide ligands in chronic lymphocytic leukaemia. Br. J. Haematol.,2002, 116, 549-554.
70. Szecsi, P.B.; Riise, E.; Roslund, L.B.; Engberg, J.; Turesson, I.; Buhl, L.; Schafer-Nielsen, C. Identification of patient-specific peptides for detection of M-proteins and myeloma cells. Br. J. Haematol.,1999, 107, 357-64.
71. Wu, P.; Leinonen, J.; Koivunen, E.; Lankinen, H.; Stenman, U. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur. J. Biochem., 2000, 267, 6212-20.
72. Romanov, V.I.; Durand, D.B.; Petrenko, V.A. Phage display selectionof peptides that affect prostate carcinoma cells attachment andinvasion. Prostate, 2001, 47, 239-251.
73. Zhang, H.; Schwab, M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett.,2001, 171, 153-164.
74. Andrea, L.D.; Iaccarino, G.; Fattorusso, R.; Sorriento, D.; Carannante, C.; Capasso, D.; Trimarco, B.; Pedone, C. Targeting angiogenesis: structural characterization and biological properties of a denovo engineered VEGF mimicking peptide. Proc. Natl. Acad. Sci.U. S. A. 2005, 102, 14215-14220.
75. Thomas Boehm, Judah Folkman, Timothy Browder & Michael S. O'Reilly Antiangiogenic therapy of experimental cancer does notinduce acquired drug resistance. Lett. Nat., 1997, 390, 404-407.
76. Essler, M.; Ruoslahti, E. Molecular specialization of breast vasculature:a breast-homing phage-displayed peptide binds to aminopeptidaseP in breast vasculature. Nat. Acad. Sci. USA, 2002, 99,2252-2257.
77. Roselyne Binétruy-Tournaire, Caroline Demangel, BernardMalavaud, Roger Vassy, Sylvie Rouyre, Michel Kraemer, JeanPlouët, Claude Derbin, Gérard Perret, Jean Claude Mazié Identificationof a peptide blocking vascular endothelial growth factor(VEGF)-mediated angiogenesis. EBMO, 2000, 19, 1525-1533.
78. Xiumei Wang, Akihiro Horii, Shuguang Zhang Designer functionalized self-assembling peptide nanofiber scaffolds for growth, migration, and tubulogenesis of human umbilical vein endothelial cells. Npg., 2008, 4, 2388-2395.
79. Froidevaux, S.; Eberle, A.N. Somatostatin analogs and radiopeptidesin cancer therapy. Biopolymers, 2002, 66, 161-183.
80. Aina, O.H.; Marik, J.; Gandour-Edwards, R.; Lam, K.S. Near-Infrared optical imaging of ovarian cancer xenografts with novelalpha 3-integrin binding peptide OA02. Mol. Imaging, 2005, 439-447.
81. Dijkgraaf, I.; Kruijtzer, J.; Liu, S.; Soede, A.; Oyen, W.; Corstens, F.; Liskamp, R.; Boerman, O. Improved targeting of the alpha(v)beta(3) integrin by multimerisation of RGD peptides. Eur. J.Nucl. Med. Mol. Imaging, 2007, 34, 267-273.
82. Ye, Y.; Bloch, S.; Xu, B.; Achilefu, S. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptidesfor targeting yumors. J. Med. Chem., 2006, 49, 2268-2275.
83. Handl, H.; Sankaranarayanan, R.; Josan, J.; Vagner, J.; Mash, E.; Gillies, R.; Hruby, V. Synthesis and evaluation of bivalent NDPalpha-MSH(7) peptide ligands for binding to the human melanocortinreceptor 4 (hMC4R). Bioconjug. Chem., 2007, 18, 1101-1109.
84. Ko, S.Y.; Guo, H.; Barengo, N.; Naora, H. Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin. Cancer Res.: An Offi. J. Am Associ. Cancer Res., 2009, 15, 4336-4347.
85. Quinn, T.P.; Karasseva, N.G. Erb-2 receptor targeting peptide.US7585509.
86. Mier, W.; Zitzmann, S.; Kramer, S.; Reed, J.; Knapp, E.-.; Altmann, A.; Eisenhut, M.; Haberkorn, U. Influence of chelate conjugationon a newly identified tumor-targeting peptide. J. Nucl. Med.,2007, 48, 1545-1552.
87. Wang, X.; Xu, R.; Lu, Z. A peptide-targeted delivery system withpH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. J. Controll. Release, 2009, 134,207-213.
88. Janssen, M.; Oyen, W.; Dijkgraaf, I.; Massuger, L.; Frielink, C.; Edwards, D.; Rajopadhye, M.; Boonstra, H.; Corstens, F.; Boerman, O. Tumor targeting with radiolabeled alpha(v)beta(3) integrinbinding peptides in a nude mouse model. Cancer Res., 2002, 62,6146-6151.
89. Tian, X.; Aruva, M.R.; Wolfe, H.R.; Qin, W.; Sauter, E.R.; Thakur, M.L.; Waldman, S.A.; Wickstrom, E. Tumor-targeting peptide-PNA-peptide chimeras for imaging overexpressed oncogenemRNAs. Nucleosides, Nucleotides Nucleic Acids, 2005, 24, 1085-1091.
90. Ivanenkov, V.V.; Felici, F.; Menon, A.G. Targeted delivery of multivalent phage display vectors into mammalian cells. Biochim. Biophys. Acta. (BBA)/Mol. Cell Res., 1999, 1448, 463-472.
91. Cyr, J.E.; Pearson, D.A.; Wilson, D.M.; Nelson, C.A.; Guaraldi, M.; Azure, M.T.; Lister-James, J.; Dinkelborg, L.M.; Dean, R.T. Somatostatin Receptor-Binding Peptides Suitable for Tumor Radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies. J. Med. Chem., 2007, 50, 1354-1364.
92. Kim, S.; Lee, S.; Tian, H.; Chen, X.; Park, T. Prostate cancer cell specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes. J. Drug Target, 2009, 17, 311-317.
93. Oh, S.; Kim, B.J.; Singh, N.P.; Lai, H.; Sasaki, T. Synthesis andanti-cancer activity of covalent conjugates of artemisinin and atransferrin-receptor targeting peptide. Cancer Letters, 2009, 274,33-39.
94. Shukla, G.S.; Murray, C.J.; Estabrook, M.; Shen, G.; Schellenberger, V.; Krag, D.N. Towards a ligand targeted enzyme prodrugtherapy: Single round panning of a β-lactamase scaffold libraryon human cancer cells. Int. J. Cancer, 2007, 120, May.
95. Oyama, T.; Sykes, K.; Samli, K.; Minna, J.; Johnston, S.; Brown, K. Isolation of lung tumor specific peptides from a random peptidelibrary: generation of diagnostic and cell-targeting reagents. CancerLett., 2003, 202, 219-230.
96. Lee, S.; Lee, E.; Hong, H.; Kwon, M.; Kwon, T.; Choi, J.; Park, R.; Kwon, T.; Yoo, E.; Yoon, G.; Kim, I.; Ruoslahti, E.; Lee, B. Targeting bladder tumor cells in-vivo and in the urine with a peptide identified by phage display. Mol. Cancer Res.,2007, 5, 11.
97. Zhang, Y.; Chen, J.; Zhang, Y.; Hu, Z.; Hu, D.; Pan, Y.; Ou, S.; Liu, G.; Yin, X.; Zhao, J.; Ren, L.; Wang, J. Panning and identification of a colon tumor binding peptide from a phage display peptide library. J. Biomol. Screen, 2007, 12, 429.
98. Rajotte, D.; Ruoslahti, E. Membrane Dipeptidase Is the Receptor for a Lung-targeting Peptide Identified by in-vivo Phage Display. J.Biol. Chem., 1999, 274, 11593-11598.
99. Erkki Kolvunen, Bingcheng Wang, Erkki Ruoslahti Phage LibrariesDisplaying Cyclic Peptides with Different Ring Sizes: LigandSpecificities of the RGD-Directed Integrins. Npg., 1995, 13, 265-270.
100. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science,1998, 279, 377-380.
101. Harris, T.; Cheesman, E.; Harris, A.; Sachleben, R.; Edwards, D.; Liu, S.; Bartis, J.; Ellars, C.; Onthank, D.; Yalamanchili, P.; Heminway, S.; Silva, P.; Robinson, S.; Lazewatsky, J.; Rajopadhye, M.; Barrett, J. Radiolabeled divalent peptidomimetic vitronectin receptorantagonists as potential tumor radiotherapeutic and imagingagents. Bioconjug. Chem., 2007, 18, 1266-1279.
102. Bae, D.; Gho, Y.; Yoon, W.; Chae, C. Arginine-rich anti-vascula rendothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J. Biol. Chem., 2000, 275, 13588-13596.
103. Xiong, J.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S.L.; Arnaout, M. Crystal Structure of the Extra cellular Segment of Integrin alpha Vbeta 3 in Complex with an Arg-Gly-AspLigand. Science (Wash.), 2002, 296, 151-155.
104. Portoghese, P.S.; Ronsisvalle, G.; Larson, D.L.; Yim, C.B.; Sayre, L.M.; Takemori, A.E.,2) Opioid agonist and antagonist bivalentligands as receptor probes. Life Sci., 1982, 31, 1283-1286.
105. Temming, K.; Lacombe, M.; Hoeven, P.v.d.; Prakash, J.; Gonzalo, T.; Dijkers, E.C.F.; Orfi, L.; Kéri, G.; Poelstra, K.; Molema, G.; Kok, R.J. Delivery of the p38 MAPkinase Inhibitor SB202190 to Angiogenic Endothelial Cells: Development of Novel RGDEquippedand PEGylated Drug-Albumin Conjugates Using Platinum(II)-Based Drug Linker Technology. Bioconjug. Chem., 2006,17, 1246-1255.
106. Temming, K.; Senter, P.D.; Meyer, D.L.; Zabinski, R.; Poelstra, K.; Molema, G.; Kok, R.J. Improved Efficacy of αvβ3-Targeted Albumin Conjugates by Conjugation of a Novel Auristatin Derivative. Mol. Pharm., 2007, 4, 686-694.
107. Zhang, C.; Jugold, M.; Woenne, E.C.; Lammers, T.; Morgenstern, B.; Mueller, M.M.; Zentgraf, H.; Bock, M.; Eisenhut, M.; Semmler, W.; Kiessling, F. Specific targeting of tumor angiogenesis byRGD-conjugated ultrasmall super paramagnetic iron oxide particle susing a clinical 1.5-T magnetic resonance scanner. Cancer Res.,2007, 67, 1555-1562.
108. Kim, W.J.; Yockman, J.W.; Jeong, J.H.; Christensen, L.V.; Lee, M.; Kim, Y.H.; Kim, S.W. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1complexes in tumor-bearing mice. J. Control. Release, 2006, 114,381-388.
109. Mitra, A.; Coleman, T.; Borgman, M.; Nan, A.; Ghandehari, H.; Line, B.R. Polymeric conjugates of mono- and bi-cyclic αV β3binding peptides for tumor targeting. J. Control. Release, 2006,114, 175-183.
110. Kunath, K.; Merdan, T.; Hegener, O.; Häberlein, H.; Kissel, T. Integrin targeting using RGD-PEI conjugates for in-vitro genetransfer. J. Gene Med., 2003, 5, 588-599.
111. Xiong, X.; Huang, Y.; Lu, W.; Zhang, X.; Zhang, H.; Nagai, T.; Zhang, Q. Intracellular delivery of doxorubicin with RGD modified sterically stabilized liposomes for an improved antitumor efficacy: in-vitro and in-vivo. J. Pharm Sci., 2005, 94, 1782-1793.
112. Koning, G.A.; Schiffelers, R.M.; Wauben, M.H.M.; Kok, R.J.; Mastrobattista, E.; Molema, G.; ten Hagen, T.L.M.; Storm, G. Targetingof angiogenic endothelial cells at sites of inflammation bydexamethasone phosphate-containing RGD peptide liposomes inhibitsexperimental arthritis. Arthritis Rheum., 2006, 54, 1198-1208.
113. Dubey, P.; Mishra, V.; Jain, S.; Mahor, S.; Vyas, S. Liposomesmodified with cyclic RGD peptide for tumor targeting. J. DrugTarget., 2004, 12, 257-264.
114. Ruoslahti, E.; Pierschbacher, M.D. Arg-Gly-Asp: A versatile cellrecognition signal. Cell. 1986, 44, 517-518.
115. Dunehoo, A.L.; Anderson, M.; Majumdar, S.; Kobayashi, N.; Berkland, C.; Siahaan, T.J. Cell adhesion molecules for targeted drugdelivery. J. Pharm. Sci., 2006, 95, 1856-1872.
116. ller, G.; Gurrath, M.; Kurz, M.; Kessler, H. βVI Turns in peptidesand proteins: A model peptide mimicry. Proteins: Struct., 1993, 15,1993.
117. Dechantsreiter, M.A.; Planker, E.; Mathä, B.; Lohof, E.; Hölzemann, G.; Jonczyk, A.; Goodman, S.L.; Kessler, H. N -Methylated Cyclic RGD Peptides as Highly Active and Selective αV β3 Integrin Antagonists. J. Med. Chem., 1999, 42, 3033-3040.
118. Lee, T.; Lin, C.; Kuo, S.; Chang, D.; Wu, H. Peptide-mediatedtargeting to tumor blood vessels of lung cancer for drug delivery.Cancer Res., 2007, 67, 10958-10965.
119. Chang, D.; Lin, C.; Wu, C.; Wu, H. A novel peptide enhancestherapeutic efficacy of liposomal anti-cancer drugs in mice modelsof human lung cancer. PloS One, 2009, 4, 4171.
120. Kim,; Yoo-Shin Kim,; Kyeongsoon Park,; Eunah Kang,; Seulki Lee,; Hae Yun Nam,; Kwangmeyung Kim,; Jae Hyung Park,; Dae Yoon Chi,; Rang-Woon Park,; In-San Kim,; Kuiwon Choi,; Ick Chan Kwon, Self-assembled glycol chitosan nanoparticles forthe sustained and prolonged delivery of antiangiogenic small peptidedrugs in cancer therapy. Biomaterials, 2008, 29, 1920-1930.
121. Collier, J.; Messersmith, P. Self-assembling polymer-peptide conjugates:Nanostructural tailoring. Adv. Mater., 2004, 11, 907-910.
122. Jung, J.P.; Nagaraj, A.K.; Fox, E.K.; Rudra, J.S.; Devgun, J.M.; Collier, J.H. Co-assembling peptides as defined matrices for endothelialcells. Biomaterials, 2009, 30, 2400-2410.